Elobixibat is an inhibitor of the ileal bile acid transporter, undergoing development in clinical trials for the treatment of chronic constipation and irritable bowel syndrome with constipation. It is a small molecule ASBT inhibitor designed for oral administration with minimal systemic exposure so that pharmacologic activity is confined to the intestinal lumen; the drug reduces ileal bile acid reuptake, increases colonic bile acid concentrations, promotes chloride and water secretion and stimulates colonic motility, resulting in accelerated colonic transit and softer stools. Key technical points include predominant local action in the gut, low plasma Cmax and AUC relative to orally absorbed drugs, metabolism and elimination primarily via fecal excretion of parent and minor metabolites, quantitation and purity assessment by reversed phase HPLC with UV and LC MS-MS confirmation, and clinical development doses evaluated in the low milligram range, commonly 5 mg and 10 mg cohorts in trials.
Parent: Elobixibat
Parent: Elobixibat
Parent: Elobixibat
Typical quality control specifications for elobixibat active pharmaceutical ingredient and finished formulations follow ICH Q3A and Q3B principles using validated HPLC and LC MS-MS methods; typical acceptance criteria used in regulatory dossiers and contract manufacturing settings include individual unidentified impurities not exceeding 0.1 percent area by HPLC, individual specified related substances limited to 0.2 to 0.5 percent each depending on qualification data, and total impurities limited to approximately 1.0 percent; known related compounds frequently monitored include de-esterified analogs, mono- and di-dealkylated products, hydroxylated metabolites and positional isomers with individual limits typically set at 0.5 percent or lower, residual solvents controlled per ICH Q3C and heavy metals per USP/EP limits, and assay specification for potency commonly set at 98.0 percent to 102.0 percent of labeled amount.
Elobixibat is being developed to treat chronic constipation and irritable bowel syndrome with constipation by increasing colonic bile acids to stimulate secretion and motility, improving stool frequency and consistency.
Clinical studies have reported laxation effects within 24 to 48 hours in many patients, with measurable improvements in bowel movement frequency and stool form across the first week of treatment; onset can vary by individual and dose.
As of the knowledge cutoff in mid 2024 elobixibat is not listed as an FDA approved treatment in the United States; regulatory status may differ by country and ongoing clinical development and marketing authorizations should be confirmed from current regulatory sources.
Bixibat 5 refers to a 5 mg formulation of elobixibat and shares the same mechanism of action: inhibition of the ileal bile acid transporter reduces bile acid reabsorption in the terminal ileum, increases luminal bile acid delivery to the colon and thereby stimulates colonic secretion and motility leading to accelerated transit and softer stools.
